

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

PQ Segment Depression in Short QT Syndrome Patients: A Novel Marker for Diagnosing Short QT Syndrome?

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/147336> since

Published version:

DOI:10.1016/j.hrthm.2014.02.024

Terms of use:

Open Access


Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Author's Accepted Manuscript

PQ Segment Depression in Short QT Syndrome Patients: A Novel Marker for Diagnosing Short QT Syndrome?

Erol Tülümen MD, Carla Giustetto MD, Christian Wolpert MD, Philippe Maury MD, Olli Anttonen MD, Vincent Probst MD, Jean-Jacques Blanc MD, Pascal Sbragia MD, Chiara Scrocco MD, Boris Rudic MD, Christian Veltmann MD, Yaxun Sun MD, Fiorenzo Gaita MD, Charles Antzelevitch PhD, Martin Borggrefe MD, PhD, Rainer Schimpf MD



www.elsevier.com/locate/buildenv

PII: S1547-5271(14)00233-1
DOI: <http://dx.doi.org/10.1016/j.hrthm.2014.02.024>
Reference: HRTM5666

To appear in: *Heart Rhythm*

Cite this article as: Erol Tülümen MD, Carla Giustetto MD, Christian Wolpert MD, Philippe Maury MD, Olli Anttonen MD, Vincent Probst MD, Jean-Jacques Blanc MD, Pascal Sbragia MD, Chiara Scrocco MD, Boris Rudic MD, Christian Veltmann MD, Yaxun Sun MD, Fiorenzo Gaita MD, Charles Antzelevitch PhD, Martin Borggrefe MD, PhD, Rainer Schimpf MD, PQ Segment Depression in Short QT Syndrome Patients: A Novel Marker for Diagnosing Short QT Syndrome?, *Heart Rhythm*, <http://dx.doi.org/10.1016/j.hrthm.2014.02.024>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

PQ Segment Depression in Short QT Syndrome Patients: A Novel Marker for Diagnosing Short QT Syndrome?

Short Title: Short QT Syndrome and PQ Segment Depression

Erol Tülümen, MD,*† §§ Carla Giustetto, MD,‡ §§ Christian Wolpert C, MD,§ Philippe Maury, MD,¶ Olli Anttonen, MD,# Vincent Probst, MD,** Jean-Jacques Blanc, MD,Δ Pascal Sbragia, MD,†† Chiara Scrocco, MD,‡ Boris Rudic, MD,*† Christian Veltmann, MD,*†, Yaxun Sun, MD,ΔΔ Fiorenzo Gaita, MD,‡ Charles Antzelevitch, PhD‡‡ Martin Borggrefe, MD, PhD*† Rainer Schimpf, MD*†

* University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany

† DZHK (German Centre for Cardiovascular Research) partner site Mannheim, Germany

‡ Division of Cardiology, Department of Medical Sciences, University of Turin, "Città della Salute e della Scienza" Hospital, Turin, Italy;

§ Department of Medicine-Cardiology, Nephrology and Internal Intensive Care Medicine, Klinikum Ludwigsburg, Ludwigsburg, Germany

¶ Federation of Cardiology, University Hospital Rangueil, Toulouse, France;

Division of Cardiology, Lahti Central Hospital, Lahti, Finland;

** Service de Cardiologie, Institut du Thorax, Université de Nantes, Nantes, France;

Δ Departement de Cardiologie, Université de Bretagne Occidentale, Hôpital de la Cavale Blanche, Brest, France;

†† Division of Cardiology, Hôpital Nord, Marseille, France

‡‡ Masonic Medical Research Laboratory, Utica, New York, USA

ΔΔ Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China

§§ Dr. Tülümen and Dr. Giustetto equally contributed to this manuscript.

Word count: Title: 16

Abstract: 217

Manuscript: 4921

Address for correspondence:

Erol Tülümen, MD

1st Department of Medicine

University Medical Centre Mannheim

Theodor-Kutzer-Ufer 1-3

68167 Mannheim

Germany

Tel.: 0049-621-383-2206

Fax.: 0049-621-383-2012

e-mail: erol.tueluemen@umm.de

Disclosures: There is no potential conflict of interest to disclose for any of the co-authors.

Abbreviations

SQTS Short QT Syndrome

ECG Electrocardiogram

PQD PQ segment depression

BACKGROUND: Patients with a short QT syndrome (SQTS) have an increased risk for atrial, ventricular tachyarrhythmias and/or sudden cardiac death. PQ segment depression (PQD) is related to atrial fibrillation and carries a poor prognosis in the setting of acute inferior myocardial infarction and is a well defined ECG marker of acute pericarditis.

OBJECTIVES: The aim of this study was to evaluate the prevalence of PQD in SQTS and to analyze the association with atrial arrhythmias.

METHODS: Digitalized 12-lead ECGs of SQTS patients were evaluated for PQD in all leads and for QT intervals in lead II and V5. PQD was defined as ≥ 0.05 mV (0.5 mm) depression from the isoelectric line.

RESULTS: A total of 760 leads from 64 SQTS patients [mean age 36 ± 18 years, 48 males (75%)] were analyzed. PQD was seen in 265 (35%) leads from 52 (81%) patients and was more frequent in leads II, V3, aVF, V4, and I [n=43 (67%), n=30 (47%), n=27 (42%), n=25 (39%), n=25 (39%), respectively]. Nine of 64 patients (14%) presented with atrial tachyarrhythmias and all of them had PQD.

CONCLUSIONS: Fifty-two of 64 patients (81%) with SQTS reveal PQD. As PQD is rarely observed in healthy subjects, this ECG stigma may constitute a novel marker for SQTS in addition to a short QT interval.

Keywords: PQ depression, short QT syndrome, sudden cardiac death, ECG

Introduction:

Short-QT-syndrome (SQTS) is a recently described highly arrhythmogenic cardiac channelopathy characterized by shortened QTc-interval, reduced atrial and ventricular effective refractory periods, and atrial and/or ventricular arrhythmias with an increased risk for familial sudden cardiac death¹. Although the hallmark of the disease is a short QT interval on ECG, a universally accepted diagnostic cut-off value of short QT interval has not been defined. SQTS was initially recognized in patients with QTc interval of 300 ms or less. However, in subsequent studies, patients with similar clinical presentations and slightly or moderately shortened QT intervals (≤ 340 -360 ms) were described²⁻⁵. Moreover, impaired QT adaptation to heart rate changes makes the correction formulas like Bazett or Fredericia inappropriate or of limited value in SQTS patients with heart rates above 100/min or below 60/min^{4, 6, 7}. Poor performance of correction formulas, in addition to lack of universal diagnostic cut-off value for a SQTS, makes it difficult to establish a diagnosis in cases of borderline shortened QT intervals. Apart from a short QT interval, the ECG pattern of the ST segment, the T wave (tall and symmetrical T waves with a short interval between the QRS offset and the onset of T wave), an abnormal J point-Tpeak interval, Tpeak-Tend/QTc intervals or frequent clear demarcation of the U-wave (especially in precordial leads), as well as the lack of adaptation of the QT interval during exercise were previously reported to be helpful to establish the diagnosis of SQTS⁸⁻¹⁰.

Beside these markers of shortened ventricular repolarization, ECG markers of atrial repolarization abnormalities may improve the diagnostic value in differentiating patients with a SQTS. The greater abbreviation of the action potential of the pectinate muscle as compared to the cristae terminalis generates a spatial dispersion of repolarization in atria, which may cause a PQ depression on ECG due to a voltage gradient¹¹. A heterogeneous shortening of atrial repolarization and a reduced wavelength lead clinically to an increased incidence of atrial fibrillation/flutter in patients with a congenital SQTS⁵. However, the impact of spatial repolarization dispersion on the PQ segment has not been established in SQTS.

PQ segment depression (PQD) is a well defined electrocardiographic marker of acute pericarditis. It is related to injury like currents and is present in the acute phase in up to 82% of patients¹². Furthermore, it is a powerful tool in the differential diagnosis of patients with STEMI¹²⁻¹⁶. PQD is also associated with extensive atrial myocardial damage, atrial fibrillation and poor prognosis in patients with an acute inferior myocardial infarction¹⁷; Finally, it has been observed during ablation of the left upper pulmonary vein or in patients with atrial tumors^{18, 19}.

The aim of this study was to evaluate the prevalence of PQD in SQTS, the value of PQD as an additional diagnostic ECG marker of SQTS.

Methods:

Study Population:

This multicenter study population consisted of 64 patients (48 males, age 36 ± 18 years, range 5-88 years) diagnosed with SQTS from a European SQTS registry⁵. In this registry, the SQTS was diagnosed: (1) if the patient had a QTc interval of 360 ms or less (in lead II or V5), with history of sudden death or aborted sudden death or syncope of arrhythmic origin; or (2) if subjects had a very short QT interval (QTc < 340 ms) (even if they were asymptomatic); or (3) if the patient had a short QT interval (QTc interval ≤ 360 ms, in lead II or V5) with a family history of SQTS.

To best of our knowledge, there is not any large scale study reporting about an abnormal or physiological PQ segment deviation in healthy subjects. Hence, we included age- and sex-matched 117 subjects as a control group without any known structural heart disease or channelopathy; to evaluate the presence and frequency of PQD in normal population and to avoid the bias and hypothesis driven false positive results due to the measurements performed in a single group.

ECG Measurements

All resting 12-lead ECGs (paper speed 25 or 50 mm/s, gain 10 mm/mV) of SQTS patients were scanned and analyzed for PQD in all leads and for QT-intervals in lead II and V5. All measurements were performed after 4-fold

magnification of the ECGs (using Adobe Acrobat 8 Professional; Adobe Systems Incorporated, San Jose, CA).

PQ segment depression was defined as ≥ 0.05 mV (0.5 mm) depression from the isoelectric line. The TP segment (the isoelectric interval between the end of T wave and the next P wave) was used as baseline for the examinations^{20 21}. If no clear-cut TP segment could be defined or in case of drifting, non-parallel TP and PQ baselines, the beat with less drifting baseline has been chosen for measurement and if it was not possible at all, the vertical distance from the beginning of P wave to the dip of PQ segment was measured (Figure 1).

In lead aVR, PQ segment elevation (≥ 0.05 mV) was accepted as equal to PQD in other leads. The ECGs of each patient were examined separately by three investigators blinded to the clinical information. In case of disagreement, decision was made by majority vote. The quantitative measurements were made by a single investigator. For intra-observer reliability analysis of quantitative measurements, a sample of 20 patients was re-analysed. The intra-observer correlation co-efficient was between 0.82 and 0.98; and variability was <16% in all leads.

The end of T wave was defined by a standard tangential method and the QT-interval was corrected for the heart rate according to Bazett's formula.

Statistical Analysis:

Numerical variables were presented as mean \pm standard deviation (SD) and when the distributions were skewed, as the median and interquartile range; categorical variables are presented as absolute numbers and percentages. The differences in mean values between groups were analyzed with Student's *t*-test for independent samples. When distribution of variable is skewed the Mann-Whitney U-test is used for comparison of 2 groups and the Kruskal-Wallis test is used for comparison of 3 groups. The categorical variables were analyzed with Pearson's chi-square test. P values < 0.05 were considered significant. The receiver operating characteristics (ROC) curve was obtained for the various PQ depression cut-off values, as a predictor of atrial fibrillation/flutter. Youden's index was calculated ($YI = \text{sensitivity} + \text{specificity} - 1$) for each coordinate point of the ROC curve to determine the cut-off value, which has the maximum sensitivity and specificity pair. Statistical analyses were performed using Statistical Package for Social Science (SPSS) for Windows version 16.0 (SPSS, Chicago, IL, USA).

Results:

Demographic, Clinical and Genetic Data

Sixty-four patients with SQTS and 117 subjects without any structural heart disease or channelopathy were included in the study. Of the 64 patients, 48 (75%) were males and the median age was 30 years (interquartile range: 23 to 44 years). Patients and controls demographic, clinical, genetic and ECG data are summarized in table 1. Thirty (47%) patients had symptoms including 18 (28%) patients with cardiac arrest (5 patients deceased), 5 (8%) patients with syncope (1 with presyncope), 9 (14%) patients with atrial fibrillation/flutter and 15 (23%) patients with ventricular premature contractions. Three of 9 patients had atrial fibrillation/flutter before 35 years of age. Initial presentation was cardiac arrest in 15 patients, syncope in 4 patients and palpitations in 5 patients.

Genetic screening was performed in 46 patients: 13 (20%) patients were identified with a gain-of-function mutation in KCNH2 (HERG) and 2(3%) patients with loss-of-function in cardiac L-type calcium channel (CACNB2b).

Electrocardiography

760 leads of 64 SQTS patients and 1404 leads of 117 controls were analyzed (8 leads of two SQTS patients were missing). QTc intervals were shown in table 1. PQD was seen in 52/64 (81%) patients and in 265/760 (35%) leads of patients (Fig. 2). PQD was seen only in 28/117 (24%) subjects and in 73/1404 (5.1%) leads of healthy subjects ($p < 0.0001$). PQD was most often found in both the

anterior and inferior leads in patients. Lead II was the most common (67%) and lead aVL was the rarest (3%) lead for PQD (Fig. 3). PQD was also most frequent in inferior leads [n=18 (15.8%) in lead II; n=9 (7.7%) in lead aVF] in healthy subjects. PQ segment elevation in aVR was found in 36% (n=23) of the patients and 6.8% (n=8) in controls. PQD was rare in other leads in control group (<10%). PQD was more prominent in the inferior leads in patients and healthy controls, especially in lead II (Fig. 2). PQD was also more prevalent in all leads in SQTS patients compared to controls (p=0.05 for aVL, p<0.001 for other leads).

QTc (II) and QTc (V5) were not significantly different between patients with PQD in any lead and without PQD in any lead in patients (Table 2).

As PQD is related to atrial repolarization, the relationship between PQD and atrial arrhythmias was evaluated: patients with PQD in any lead vs. patients without any PQD; or presence of PQD in every lead separately.

There was no significant association between the prevalence of PQD and atrial arrhythmias. However, all of 9 patients with atrial fibrillation/flutter had PQD at least in one lead. We also conducted quantitative measurements of PQ depression and found that the patients with atrial arrhythmias had significantly more prominent PQ depression in leads II, III and aVF, i.e. inferior leads. (0.44 mm vs 0.78 mm, p:0.01; 0.17 mm vs. 0.48 mm, p:0.005 ; 0.28 mm vs. 0.66 mm, p:0.004, respectively). The cut-off values for atrial arrhythmias in leads II, III, aVF were 0.66 mm, 0.59 mm, 0.42 mm, respectively (sensitivity 67%, 67%,

89%; specificity 80%, 82%, 65%, respectively). There was no significant difference in quantitative PQ depression in any other leads. Quantitative measurements of PQ depression were similar in all leads between patients with and without syncope or cardiac arrest (data not shown).

There was also no significant difference between patients with and without PQD in any lead in terms of gender, age, QT intervals, cardiac arrest, and syncope (Table 3).

Accepted manuscript

Discussion:

SQTS is a recently recognized cardiac channelopathy with an increased risk of life-threatening ventricular tachyarrhythmias and sudden cardiac death¹. The major hallmark of the disease is a short QT interval. However, there is no clear cut-off value of short QT interval. Additional ECG markers like short or absent ST segment with tall, narrow, peaked, symmetrical T waves, presence of delineated U waves in precordial leads, or additional intervals like Tpeak-Tend, Tpeak-Tend/QTc, Jpoint-Tpeak may be helpful to ensure the diagnosis especially in patients with borderline QTc intervals (QTc 340-370 ms). In the present study, we conducted an analysis of ECGs of SQTS patients from European SQTS registry and observed that PQD is very frequent in SQTS patients.

The patients with QTc interval less than 320 ms were diagnosed with SQTS in early reports^{1, 6, 22, 23}. Thereafter, Bjerregaard and coworkers²⁴ proposed QTc < 350 ms as a short QT interval (<88% of the mean predicted value) and < 320 ms as a very short QT interval (<80% of the mean predicted value) based on Rataharju's ECG analyses of 14379 healthy individuals²⁵. Viskin et al demonstrated that male patients with idiopathic ventricular fibrillation had shorter QT intervals (371±22 ms) and suggested gender specific cut-off values (QTc < 360 ms for males, QTc < 370 ms for females) for short QT interval². In several population based studies, the lower limit of QT intervals were identified between 332-380 ms for males and 344-390 ms for females²⁶⁻³¹. It has also been

shown that very short QT intervals (<300 ms) are very rare and a moderately shortened QT interval (<340 ms) does not always indicate an increased risk of sudden death^{7, 26, 31, 32}. Nevertheless, there is still no clear consensus for the diagnostic cut-off value of QTc interval. In our patient population the mean QTc (II) and (V5) intervals were 320.9 ± 29.4 ms (range 242-368 ms) and 322.1 ± 27.9 ms (range 248-364 ms), respectively, though 18 patients had QTc (II)-interval longer than 340 ms. Moreover, contrary to population based studies with short QT interval subjects, cardiac arrest was the initial presentation in 18 of 65 patients. For the diagnosis of SQTS, especially with borderline shortened QT intervals, underlying conditions (hyperkalemia, hypercalcemia, hyperthermia, acidosis and digitalis overdose) should be excluded, other ECG patterns (T wave morphology, PQD, or presence of prominent U wave) should also be taken into consideration and genetic screening should be initiated^{33, 34}.

The mutations of cardiac ion channels (gain of function of K channels - KCNH2, KCNQ1, KCNJ2) and loss of function of cardiac L-type Ca channels (CACNA1C, CACNB2b, CACNA2D1) operating in phase 2 and 3 of the cardiac action potential are responsible for the abbreviation of action potential duration^{23, 35-38}. These mutations lead to heterogenous abbreviation of the action potential duration (preferentially more on epi- and endocardial layers), to a shortened QT interval and also to peaked T wave, and ST segment elevation on the ECG^{11, 39}. Antzelevitch et al proposed the heterogeneous shortening of action potential duration among the three layers of myocardium [increased transmural

dispersion of repolarization (TDR)] and the decreased wavelength of activation as the mechanism of the arrhythmogenicity in SQTs^{11,39}.

Similarly, the presence of PQD in SQTs patients may be due to heterogeneous abbreviation of atrial repolarization, which is expected to manifest as a deviation in the voltage of the PQ segment. In both animals and humans, the atria are comprised of diverse cell types whose action potential morphologies differ because of differences in the contribution of outward and inward ion channel currents⁴⁰⁻⁴². Atrial cells in the crista terminalis and the pectinate muscle have ion channels with different kinetic properties creating spatial dispersion of action potential duration between the crista terminalis and pectinate muscles as well as between atrial epicardium and endocardium¹¹. This spatial dispersion of repolarization and attendant dispersion of refractoriness contributes to the development of arrhythmogenesis in the atria^{41,43}. The SQT1 form of the short QT syndrome has been shown to be associated with mutations in KCNH2, which cause a gain-of-function of I_{Kr} ³⁵. Using a coronary-perfused canine atrial preparation, Nof et al showed that the I_{Kr} agonist PD-118057 is capable of recapitulating the electrophysiologic and arrhythmic manifestations of SQT1¹¹. Abbreviation of action potential duration and effective refractory period together with amplification of spatial dispersion of repolarization predisposed to the development of atrial fibrillation by creating the substrate for reentry. The spatial dispersion of repolarization developed as a consequence of the greater abbreviation of the action potential of the pectinate muscle as compared to the

cristae terminalis. This heterogeneous action of the I_{Kr} agonist created a voltage gradient at the level of the action potential plateau, giving rise to a depression in the pseudo-ECG. This depression is expected to cause a PQ depression in the body surface ECG¹¹.

PQD is also seen up to 24% in control group (mostly due to PQD in lead II). One of the possible explanation for this phenomenon in healthy subjects might be simply the augmentation of the atrial T wave in some patients (as it is more prominent and prevalent in lead II). Another plausible explanation could be the increased spatial dispersion in atria in otherwise healthy subjects as in SQTS patients. However, the exact mechanism for PQD in healthy subject, as well as the clinical implications of PQD in healthy subjects (whether PQD is a predictor for atrial arrhythmias or other clinical events in the future) remains unknown and requires further studies.

In previous studies, PQD was shown to be a prognostic indicator of atrial fibrillation and poor outcome in several clinical situations^{17, 44-47}. In accordance with previous studies, we found that patients with atrial arrhythmias had significantly more pronounced PQ depression in inferior leads, supporting the proposed mechanism of heterogeneous abbreviation of action potentials and consequent spatial repolarization dispersion and voltage gradient presenting as PQD and increased risk of arrhythmias in SQTS.

PQD has also been shown to occur rarely during the left upper pulmonary vein ablation or atrial tumors^{18, 19}. In acute pericarditis, likewise, PQD is presented in

about 80% of the patients and it also occurs earlier than ST elevation in course¹²
⁴⁸. Proposed mechanism of PQD in these settings is the transient increase in the
magnitude (without change in direction) of the atrial repolarization vector due to
injury currents^{12, 18}. In acute pericarditis, ST elevation and PQD share the same
mechanism, which is the injury current due to epimyocarditis. Ventricular
epimyocarditis manifests as ST elevation and atrial epimyocarditis manifests as
PQD. As in acute pericarditis, PQD is present in 81% of SQTs patients, and
more prevalent and prominent in inferior and anterior leads consistent with the
direction of the atrial repolarization vector.

Limitations:

Our study has several limitations. The lack of control group consisted of subjects with borderline QT intervals is one of the limitations in the present study. Nevertheless, healthy subjects with borderline QT-interval are extremely rare to constitute a control group and the question whether these subjects are so far asymptomatic SQTS patients or healthy subject with QT interval in very lower physiological border, would remain unanswered. Therefore, we included age- and sex-matched subjects with normal QT intervals without any structural heart disease or channelopathy as a control group to compare the presence and frequency of PQD in healthy subjects with SQTS patients.

Measurement related issues are the other limitations of our study. Tachycardia or drifting baselines may interfere with measurement of the PQD, and also the risks related to manual measurements could not be totally excluded.

Another limitation of the present study is the predefined cut-off value of 0.5 mm. This value was chosen according to previous studies^{20, 21, 44-46}. However, this cut-off value was used for definition of PQD in pericarditis or atrial infarction and might not be appropriate to assess the PQD in STQS.

Conclusion:

In this study, we showed a significantly high prevalence (81% of patients) of PQD in SQTS. The association between the degree of PQD in inferior leads and atrial arrhythmias suggests that an augmented TDR and resulting currents in atria may be the operative mechanism. This frequent ECG pattern in SQTS reflecting augmented atrial TDR may constitute a novel marker for SQTS in addition to a short QT interval.

Accepted manuscript

References:

1. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, Richiardi E, Borggrefe M. Short QT Syndrome: a familial cause of sudden death. *Circulation* Aug 26 2003;108:965-970.
2. Viskin S, Zeltser D, Ish-Shalom M, Katz A, Glikson M, Justo D, Tekes-Manova D, Belhassen B. Is idiopathic ventricular fibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. *Heart Rhythm* Nov 2004;1:587-591.
3. Watanabe H, Makiyama T, Koyama T, et al. High prevalence of early repolarization in short QT syndrome. *Heart Rhythm* May 2010;7:647-652.
4. Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M. Short QT syndrome. *Cardiovasc Res* Aug 15 2005;67:357-366.
5. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, Probst V, Blanc JJ, Sbragia P, Dalmaso P, Borggrefe M, Gaita F. Long-term follow-up of patients with short QT syndrome. *J Am Coll Cardiol* Aug 2 2011;58:587-595.
6. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P, Leone G, Maury P, Anttonen O, Haissaguerre M, Gaita F. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. *Eur Heart J* Oct 2006;27:2440-2447.
7. Kobza R, Roos M, Niggli B, Abacherli R, Lupi GA, Frey F, Schmid JJ, Erne P. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. *Heart Rhythm* May 2009;6:652-657.
8. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. *J Cardiovasc Electrophysiol* Jan 2005;16:54-58.
9. Anttonen O, Junttila MJ, Maury P, et al. Differences in twelve-lead electrocardiogram between symptomatic and asymptomatic subjects with short QT interval. *Heart Rhythm* Feb 2009;6:267-271.
10. Schimpf R, Antzelevitch C, Haghi D, Giustetto C, Pizzuti A, Gaita F, Veltmann C, Wolpert C, Borggrefe M. Electromechanical coupling in patients with the short QT syndrome: further insights into the mechano-electrical hypothesis of the U wave. *Heart Rhythm* Feb 2008;5:241-245.
11. Nof E, Burashnikov A, Antzelevitch C. Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. *Heart Rhythm* 2010;7:251-257.

12. Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis. Significance of PR segment and PR vector changes. *Circulation* Sep 1973;48:575-580.
13. Porela P, Kyto V, Nikus K, Eskola M, Airaksinen KE. PR depression is useful in the differential diagnosis of myopericarditis and ST elevation myocardial infarction. *Ann Noninvasive Electrocardiol* Apr 2012;17:141-145.
14. Ginzton LE, Laks MM. The differential diagnosis of acute pericarditis from the normal variant: new electrocardiographic criteria. *Circulation* May 1982;65:1004-1009.
15. Bruce MA, Spodick DH. Atypical electrocardiogram in acute pericarditis: characteristics and prevalence. *J Electrocardiol* 1980;13:61-66.
16. Baljepally R, Spodick DH. PR-segment deviation as the initial electrocardiographic response in acute pericarditis. *Am J Cardiol* Jun 15 1998;81:1505-1506.
17. Jim MH, Siu CW, Chan AO, Chan RH, Lee SW, Lau CP. Prognostic implications of PR-segment depression in inferior leads in acute inferior myocardial infarction. *Clin Cardiol* Aug 2006;29:363-368.
18. Sorgente A, Chierchia GB, Brugada P. PR-segment deviation during cryoballoon ablation. *Europace* Dec 2010;12:1761.
19. Goldberger AL, Ludwig M. Metastatic atrial tumor: case report with electrocardiographic-pathologic correlation. *J Electrocardiol* Jul 1978;11:297-300.
20. Kudo Y, Yamasaki F, Doi Y, Sugiura T. Clinical correlates of PR-segment depression in asymptomatic patients with pericardial effusion. *J Am Coll Cardiol* Jun 19 2002;39:2000-2004.
21. Chan TC, Brady WJ, Pollack M. Electrocardiographic manifestations: acute myopericarditis. *J Emerg Med* Sep-Oct 1999;17:865-872.
22. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR, Bjerregaard P. Idiopathic short QT interval: a new clinical syndrome? *Cardiology* 2000;94:99-102.
23. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. *Circ Res* Apr 15 2005;96:800-807.
24. Bjerregaard P, Gussak I. Short QT syndrome: mechanisms, diagnosis and treatment. *Nat Clin Pract Cardiovasc Med* Feb 2005;2:84-87.
25. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, Davignon A. Sex differences in the evolution of the electrocardiographic QT interval with age. *Can J Cardiol* Sep 1992;8:690-695.
26. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. *Circulation* Aug 14 2007;116:714-720.

27. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). *Am J Cardiol* Sep 15 1992;70:797-801.
28. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. *N Engl J Med* Sep 17 1992;327:846-852.
29. Rautaharju PM, Prineas RJ, Kadish A, Larson JC, Hsia J, Lund B. Normal standards for QT and QT subintervals derived from a large ethnically diverse population of women aged 50 to 79 years (the Women's Health Initiative [WHI]). *Am J Cardiol* Mar 1 2006;97:730-737.
30. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. *J Electrocardiol* Jul 2007;40:228-234.
31. Bjerregaard P, Nallapaneni H, Gussak I. Short QT interval in clinical practice. *J Electrocardiol* Sep-Oct 2010;43:390-395.
32. Gallagher MM, Magliano G, Yap YG, Padula M, Morgia V, Postorino C, Di Liberato F, Leo R, Borzi M, Romeo F. Distribution and prognostic significance of QT intervals in the lowest half centile in 12,012 apparently healthy persons. *Am J Cardiol* Oct 1 2006;98:933-935.
33. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. *Circulation* Dec 5 2000;102:2849-2855.
34. Cheng TO. Digitalis administration: an underappreciated but common cause of short QT interval. *Circulation* Mar 9 2004;109:e152; author reply e152.
35. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. *Circulation* Jan 6 2004;109:30-35.
36. Belloq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, Baro I, Wilde AA. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. *Circulation* May 25 2004;109:2394-2397.
37. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. *Circulation* Jan 30 2007;115:442-449.
38. Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). *Eur Heart J* May 2011;32:1077-1088.
39. Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. *Circulation* Dec 14 2004;110:3661-3666.

40. Wang Z, Fermini B, Nattel S. Rapid and slow components of delayed rectifier current in human atrial myocytes. *Cardiovasc Res* Oct 1994;28:1540-1546.
41. Burashnikov A, Mannava S, Antzelevitch C. Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. *Am J Physiol Heart Circ Physiol* Jun 2004;286:H2393-2400.
42. Feng J, Yue L, Wang Z, Nattel S. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. *Circ Res* Sep 7 1998;83:541-551.
43. Schuessler RB, Kawamoto T, Hand DE, Mitsuno M, Bromberg BI, Cox JL, Boineau JP. Simultaneous epicardial and endocardial activation sequence mapping in the isolated canine right atrium. *Circulation* Jul 1993;88:250-263.
44. Nagahama Y, Sugiura T, Takehana K, Tarumi N, Iwasaka T, Inada M. PQ segment depression in acute Q wave inferior wall myocardial infarction. *Circulation* Feb 1 1995;91:641-644.
45. Nagahama Y, Sugiura T, Takehana K, Tarumi N, Iwasaka T, Inada M. Clinical significance of PQ segment depression in acute Q wave anterior wall myocardial infarction. *J Am Coll Cardiol* Mar 15 1994;23:885-890.
46. Nagahama Y, Sugiura T, Takehana K, Hatada K, Inada M, Iwasaka T. The role of infarction-associated pericarditis on the occurrence of atrial fibrillation. *Eur Heart J* Feb 1998;19:287-292.
47. Flugelman MY, Hasin Y, Shefer A, Sebbag D, Freiman I, Gotsman MS. Atrial fibrillation in acute myocardial infarction. *Isr J Med Sci* May 1986;22:355-359.
48. Spodick DH. Electrocardiogram in acute pericarditis. Distributions of morphologic and axial changes by stages. *Am J Cardiol* Apr 1974;33:470-474.

Tables and Figures:

Table 1. Patients and controls demographical, clinical, genetic and basal ECG data.

Table 2. QTc-intervals in SQTS patients with and without PQD according to leads

Table 3. QT intervals and clinical events in SQTS patients with PQD in at least one lead and without any PQD

Accepted manuscript

Figure Legends

Figure 1. Measurement of PQ-segment depression with (A) and without (B) clear-cut TP segment (without clear-cut TP segment the vertical distance from the beginning of P wave to the dip of PR segment was measured)

Figure 2. Twelve-Lead electrocardiogram of a patient with a short QT syndrome showing PQ depression (small arrows indicating PQD in leads II, aVF, V3-4).

Figure 3. Distribution of PQD in relation to ECG leads (Values are n (%); PQD is presented in red sections; values under diagrams are median value and interquartile range for PQD in each lead)

Tables:**Table 1.** Patients and controls demographical, clinical, genetic and basal ECG data.

	Patients (n=64)	Controls (n=117)	P-value
Age in years (Median, IQR)	30 (IQR: 21)	36 (IQR: 38)	0.28
Male sex, n (%)	48 (75%)	72 (62%)	0.07
Baseline Heart Rate (mean ± SD)	79±21	72±14	0.02
Cardiac arrest, n (%)	18 (28%)	-	
Syncope, n (%)	5 (8%)	-	
Atrial fibrillation/Flutter, n (%)	9 (14%)	-	
ECG Intervals, ms			
QTc (II) (mean ± SD)	320.9 ± 29.4	414.2± 27.7	0.0001
Genetic Screening, n (%)	46 (72%)	-	
KCNH2(HERG)	13 (20%)		
Mutation			
CACNB2b Mutation	2 (3%)		
PQD in any lead, n (%)	52 (81%)	28 (24%)	0.0001

IQR: Interquartile Range; Values are n (%) or mean ± SD

Table 2. QTc-intervals in patients with and without PQD according to leads in

SQTS patients

Lead (PQD)	QTc (II)			QTc (V5)		
	PQD (-)	PQD (+)	<i>P</i>	PQD (-)	PQD (+)	<i>P</i>
I	322.3±30.0	320.4±28.2	0.8	321.5±29.8	324.1±24.9	0.7
II	313.9±28.4	325.1±29.0	0.1	314.8±26.0	326.2±28.2	0.1
III	318.2±26.6	331.4±34.5	0.1	319.2±26.5	332.6±29.9	0.1
aVR	320.0±26.9	322.4±33.9	0.7	321.7±27.8	322.7±28.6	0.8
aVL	321.9±28.2	287.7±57.4	0.1	322.5±28.1	306.8±15.2	0.4
aVF	317.1±26.6	326.0±32.5	0.2	316.8±25.3	329.3±30.0	0.07
V1	319.2±31.7	325.0±22.6	0.4	322.1±29.3	322.0±24.8	0.9
V2	324.3±28.2	315.5±30.8	0.2	323.7±26.1	319.4±30.8	0.5
V3	322.9±29.1	317.3±29.5	0.4	322.2±26.1	320.5±29.6	0.8
V4	324.6±29.9	316.8±27.7	0.3	324.0±26.5	320.3±30.0	0.6
V5	322.6±28.7	316.6±31.0	0.4	321.7±25.7	322.4±32.8	0.9
V6	322.4±27.9	325.4±33.7	0.5	320.3±25.9	330.3±33.6	0.2


Values are mean ± SD

Table 3. QT intervals and clinical events in SQTS patients with PQD in at least one lead and without any PQD

Variable	PQD (+) in at least one	PQD (-)	P value
	lead (n=52)	(n=12)	
Male/ Female gender	37 (71%)/15(29%)	11(92%)/1(8%)	0.2
Age, year	36±17	38±24	0.6
QTc (II), ms	321.1±30.8	319.6±22.7	0.8
QTc (V5), ms	323.4±28.5	315.9±25.0	0.4
Cardiac arrest	17 (32%)	1 (8%)	0.08
Syncope	5 (9%)	0	--
Atrial fibrillation/flutter	9 (17%)	0	--

Values are n (%) or mean ± SD

Figure 1






Figure 2




Figure 3